---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-26-000854"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2026-05-13T20:25:45+00:00"
generated_at: "2026-05-13T21:46:36.833240+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical reports Q1 2026 net loss of $6.8M; SLIM-1 trial on track for mid-2026

## Summary
- Net loss of $6.8M in Q1 2026, up from $6.3M in Q1 2025; R&D expense $4.4M (+4% YoY).
- Cash, equivalents and capital commitments of $28M expected to fund operations through first half of 2027.
- Raised $9.7M in financing in Q1 2026, including $2.2M from a registered direct offering.
- SLIM-1 Phase 1 trial of NPM-139 semaglutide implant to start mid-2026; top-line results by end of 2026.
- Cortigent spin-off or IPO under consideration; S-1 amendment filed May 13, 2026.

## SEC filing metadata
- accession: 0001753926-26-000854
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2026-05-13T20:25:45+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392626000854/0001753926-26-000854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392626000854/vani-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-26-000854
- JSON: https://secwatch.observer/filing/0001753926-26-000854.json
- Plain text: https://secwatch.observer/filing/0001753926-26-000854.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.